10-Q: Solsence Q2 2025 Revenue Soars 56%, Net Income Triples

Solsence, Inc. reported significant revenue and net income growth for Q2 2025, driven by strong performance in consumer products and a strategic shift to skin health.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 56.1% to $20,359,000, up from $13,046,000 in the same period of 2024.
• Net income for the three months ended June 30, 2025, surged by 211.6% to $2,667,000, compared to $856,000 in the prior year period.
• For the six months ended June 30, 2025, total revenue grew 52.7% to $34,984,000, and net income increased 57.2% to $2,747,000.
• The company successfully rebranded from Nanophase Technologies Corporation to Solsence, Inc. and uplisted its stock to Nasdaq under the symbol SLSN.
• Strategic focus has shifted primarily to skin health products, including consumer products and Active Pharmaceutical Ingredients (APIs), with strong demand noted in these areas.
• Solsence received $1,729,000 from the Employee Retention Credit (ERC) program and $272,000 in related interest in June 2025, recognizing $1,234,000 as other income and $194,000 as interest income, while creating a $572,000 reserve for a discrepancy.

Sentiment

Score: 8

Explanation: Strong financial performance with significant revenue and net income growth, successful rebranding and Nasdaq uplisting, and a clear strategic focus on high-growth markets. While there are operational challenges and reliance on related party debt, the overall trajectory is highly positive.

Positives

• Total revenue increased by 56.1% for the three months ended June 30, 2025, reaching $20,359,000, and by 52.7% for the six months ended June 30, 2025, reaching $34,984,000, compared to the same periods in 2024.
• Net income significantly increased by 211.6% to $2,667,000 for Q2 2025 and by 57.2% to $2,747,000 for the six months ended June 30, 2025, compared to the prior year periods.
• Gross profit improved by 57.1% to $5,877,000 in Q2 2025 and by 26.5% to $9,259,000 for the six months ended June 30, 2025.
• Cash balance increased to $4,108,000 as of June 30, 2025, from $1,409,000 at December 31, 2024.
• Successful rebranding to Solsence, Inc. and uplisting to Nasdaq (SLSN) enhance market visibility and access to capital.
• Strategic shift to focus on high-growth skin health markets (consumer products and APIs) is yielding strong demand and sales.
• Expanded borrowing limits and extended maturities on related party lines of credit and term loans to April 30, 2027, providing financial flexibility.
• Received $1,729,000 from the Employee Retention Credit (ERC) program, positively impacting other income.

Negatives

• Net cash used in operating activities increased significantly to $7,875,000 for the six months ended June 30, 2025, compared to $4,420,000 in the prior year, primarily due to increased accounts receivable and decreased deferred revenue.
• Manufacturing operating inefficiencies and facilities improvements contributed to increased cost of revenue.
• Gross margin percentage was negatively impacted by higher material costs, despite efforts to pass through costs.
• Increased operating expenses, including research and development (up 10.5% in Q2) and selling, general and administrative (up 64.7% in Q2), due to higher salaries, legal costs, and uplisting expenses.
• Dependence on a limited number of key customers, with three customers accounting for 73% of Q2 2025 revenue and 54% of YTD 2025 revenue.
• Exclusive supply agreements with BASF Corporation include contingencies that could result in the sale of production equipment and loss of significant revenue if performance requirements are not met.

Risks

• Ability to achieve consistent profitability despite historical losses.
• High dependence on a limited number of key customers, making the company vulnerable to order cancellations or changes in supply agreements.
• Specific terms in supply agreements with BASF Corporation could mandate the sale of production equipment to BASF, leading to a loss of significant revenue.
• Potential inability to secure working capital on acceptable terms or at all.
• Challenges in obtaining raw materials, including Rare Earth elements (specifically cerium oxide) and high purity zinc, at costs that can be passed on to customers.
• Uncertainty regarding future demand for and market acceptance of Solsence products and advanced materials.
• Limitations in manufacturing capacity and product mix flexibility in response to fluctuating customer demand.
• Limited marketing experience, particularly with the new suite of Solsence consumer products.
• Risks associated with changes in development and distribution relationships.
• Impact of competitive products and technologies on market share and profitability.
• Reliance on patents and the ability to protect proprietary information.
• Challenges in maintaining an appropriate electronic trading venue for securities.
• Potential impact of new governmental regulations, especially those concerning nanomaterials, which could be costly or difficult to comply with.
• Risk of business interruptions due to unexpected events or public health crises.
• Potential involvement in litigation or other legal proceedings.
• The IRS reserves the right to audit Employee Retention Credit (ERC) payments for several years after they were requested, creating a contingent liability of $572,000.

Future Outlook

The company expects continued growth, particularly in consumer products, driven by its technology and favorable market conditions. Management anticipates that increased product revenue volume will lead to more efficient absorption of fixed manufacturing costs and improved margins. Capital spending for 2025 is projected to be between $1,000,000 and $3,000,000, to be funded by profit from operations, existing loans, and potentially new debt financing.

Management Comments

• "Management believes that this growth is happening now due to a confluence of our technology and market conditions that favor the types of products we produce."
• "We continue to see unprecedented demand for these products."
• "Coupled with our expanded and growing expertise in these areas, we believe we are well positioned to enjoy growth into the future."
• "This success had led us to focus our combined business, ingredient technology, and product-development capabilities on products that bring unique performance to this area."
• "While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus, and we expect it to make up less of our total business over time."
• "Our most critical operational issue today is reducing controllable variable product manufacturing costs."

Industry Context

Solsence's strategic pivot towards skin health and consumer products aligns with growing consumer demand for "clean and inclusive beauty" and products with enhanced efficacy and aesthetic qualities. The company's integrated technology platform and vertical integration position it to capitalize on these trends, differentiating itself through proprietary mineral-based technologies and specialized formulation know-how. The decreased demand for medical diagnostics ingredients and the de-emphasis on legacy advanced materials reflect a focused response to evolving market opportunities.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• However, the significant revenue growth of 56.1% in Q2 2025 and 52.7% YTD 2025, along with a 211.6% increase in Q2 net income, suggests performance that is likely above average for many companies, especially given the strategic shift and market uplisting.
• The company's focus on "clean and inclusive beauty" and "Active Stress Defense Technology" positions it within a high-growth segment of the personal care and cosmetics industry, which generally commands higher margins and consumer interest compared to traditional industrial materials.
• The reliance on a few key customers (73% of Q2 revenue from top three) is a common characteristic in specialized B2B ingredient and private-label manufacturing, but it also presents concentration risk compared to more diversified consumer brands.

Related Party Transactions

• The company has significant lines of credit and term loans with Beachcorp, LLC and Strandler, LLC.
• Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the company's common stock.
• Mr. Bradford T. Whitmore is the brother of Ms. R. Janet Whitmore, a director of the company and the chair of the board of directors.
• As of June 30, 2025, outstanding balances with Beachcorp, LLC were $15,599,000 and with Strandler, LLC were $1,000,000.
• The A/R Revolver Facility, Inventory Facility, and New Term Loan with these related parties are secured by all unencumbered assets of the company and are subordinated to the credit facility with Libertyville Bank & Trust.
• Interest expense to related parties was $282,000 for Q2 2025 and $458,000 for YTD 2025.
• Accrued interest expense to related parties was $104,000 as of June 30, 2025.
• The company expanded the limit on the A/R Revolver Facility from $8,000,000 to $12,000,000 and the Inventory Revolver Facility from $5,200,000 to $10,000,000, extending their maturities to April 30, 2027. The Term Maturity Note maturity was also extended to April 30, 2027.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue and net income growth, successful Nasdaq uplisting, and strategic focus on high-growth markets, potentially leading to increased shareholder value. Dilution from stock option exercises is minimal compared to overall growth.
• Employees: Increased employee-related costs and salaries indicate potential benefits for employees, aligning with growth and R&D efforts.
• Customers: Strong demand for Solsence's consumer products and APIs suggests high customer satisfaction and continued partnership opportunities. However, dependence on a few key customers introduces concentration risk.
• Suppliers: Increased production volume implies higher demand for materials and supplies, benefiting suppliers, though the company notes challenges in passing through 100% of raw material price increases.
• Creditors: Extended maturities and increased borrowing capacities on related party loans provide stability for existing creditors, though the increased net cash used in operating activities might be a point of monitoring.

Next Steps

• Continue to expand efforts in skin health markets (consumer products and APIs).
• Focus on increasing throughput and improving cost efficiency in manufacturing to achieve greater scale.
• Reduce controllable variable product manufacturing costs.
• Develop new product formulations and related new technologies.
• Advance medical diagnostics ingredient knowledge.
• Enhance manufacturing processes.
• Develop or obtain additional core materials technologies.
• Continue to improve core technologies to reduce costs.
• Monitor and adjust pricing to pass through raw material cost increases.
• Potentially seek new debt financing for capital expenditures.

Key Dates

Recommendation

The company demonstrates exceptional financial performance with substantial revenue and net income growth, driven by a successful strategic pivot into high-demand skin health markets. The uplisting to Nasdaq enhances visibility and liquidity, potentially attracting broader institutional investment. While operational inefficiencies and reliance on related party debt are noted, the strong top-line and bottom-line expansion, coupled with a clear growth strategy and increasing cash reserves, indicate significant upside potential. The current valuation, in light of this growth trajectory, presents a compelling investment opportunity.

Keywords

Solsence, Nanophase Technologies, SEC Filing, 10-Q, Quarterly Report, Financial Results, Revenue Growth, Net Income, Skin Health, Consumer Products, APIs, Advanced Materials, Nasdaq Uplisting, Employee Retention Credit, Related Party Debt, Manufacturing Efficiency, Corporate Rebranding